These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


136 related items for PubMed ID: 31707329

  • 1. International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.
    Bhatt AS, Luo N, Solomon N, Pagidipati NJ, Ambrosio G, Green JB, McGuire DK, Standl E, Cornel JH, Halvorsen S, Lopes RD, White HD, Holman RR, Peterson ED, Mentz RJ, TECOS Study Group.
    Am Heart J; 2019 Dec; 218():57-65. PubMed ID: 31707329
    [Abstract] [Full Text] [Related]

  • 2. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR, TECOS Executive Committee.
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [Abstract] [Full Text] [Related]

  • 3. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Shavadia JS, Zheng Y, Green JB, Armstrong PW, Westerhout CM, McGuire DK, Cornel JH, Holman RR, Peterson ED.
    Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
    [Abstract] [Full Text] [Related]

  • 4. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
    Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, Halvorsen S, Strandberg TE, Delibasi T, Holman RR, Peterson ED, TECOS Study Group.
    Circulation; 2017 Sep 26; 136(13):1193-1203. PubMed ID: 28626088
    [Abstract] [Full Text] [Related]

  • 5. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
    McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED, Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group.
    JAMA Cardiol; 2016 May 01; 1(2):126-35. PubMed ID: 27437883
    [Abstract] [Full Text] [Related]

  • 6. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP, Vaduganathan M, Mentz RJ, Greene SJ, Subačius H, Konstam MA, Maggioni AP, Swedberg K, Gheorghiade M.
    Am Heart J; 2013 Feb 01; 165(2):216-25. PubMed ID: 23351825
    [Abstract] [Full Text] [Related]

  • 7. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas.
    Dewan P, Jhund PS, Shen L, Petrie MC, Abraham WT, Atif Ali M, Chen CH, Desai AS, Dickstein K, Huang J, Kiatchoosakun S, Kim KS, Køber L, Lai WT, Liao Y, Mogensen UM, Oh BH, Packer M, Rouleau JL, Shi V, Sibulo AS, Solomon SD, Sritara P, Swedberg K, Tsutsui H, Zile MR, McMurray JJV.
    Eur J Heart Fail; 2019 May 01; 21(5):577-587. PubMed ID: 30536678
    [Abstract] [Full Text] [Related]

  • 8. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
    Silverman DN, Plante TB, Infeld M, Callas PW, Juraschek SP, Dougherty GB, Meyer M.
    JAMA Netw Open; 2019 Dec 02; 2(12):e1916598. PubMed ID: 31800067
    [Abstract] [Full Text] [Related]

  • 9. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
    Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, Anker SD, Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen CH, Chopra VK, Cleland J, Comin-Colet J, Duengen HD, Echeverría Correa LE, Filippatos G, Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens S, Katova T, Køber L, Lelonek M, Linssen G, Lund LH, O'Meara E, Merkely B, Milicic D, Oh BH, Perrone SV, Ranjith N, Saito Y, Saraiva JF, Shah S, Seferovic PM, Senni M, Sibulo AS, Sim D, Sweitzer NK, Taurio J, Vinereanu D, Vrtovec B, Widimský J, Yilmaz MB, Zhou J, Zweiker R, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV.
    Circ Heart Fail; 2018 Jul 02; 11(7):e004962. PubMed ID: 29980595
    [Abstract] [Full Text] [Related]

  • 10. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
    Nauck MA, McGuire DK, Pieper KS, Lokhnygina Y, Strandberg TE, Riefflin A, Delibasi T, Peterson ED, White HD, Scott R, Holman RR.
    Cardiovasc Diabetol; 2019 Sep 03; 18(1):116. PubMed ID: 31481069
    [Abstract] [Full Text] [Related]

  • 11. Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial.
    Greene SJ, Fonarow GC, Solomon SD, Subacius H, Maggioni AP, Böhm M, Lewis EF, Zannad F, Gheorghiade M, ASTRONAUT Investigators and Coordinators.
    Eur J Heart Fail; 2015 Jun 03; 17(6):591-600. PubMed ID: 25930208
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB, Gantz I, McGuire DK, VERTIS CV Investigators.
    Circulation; 2020 Dec 08; 142(23):2205-2215. PubMed ID: 33026243
    [Abstract] [Full Text] [Related]

  • 13. International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
    Harumi Higuchi Dos Santos M, Sharma A, Sun JL, Pieper K, McMurray JJ, Holman RR, Lopes RD.
    J Am Heart Assoc; 2017 Jan 13; 6(1):. PubMed ID: 28087508
    [Abstract] [Full Text] [Related]

  • 14. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy.
    Shen L, Ramires F, Martinez F, Bodanese LC, Echeverría LE, Gómez EA, Abraham WT, Dickstein K, Køber L, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Jhund PS, Gimpelewicz CR, McMurray JJV, PARADIGM-HF and ATMOSPHERE Investigators and Committees.
    Circ Heart Fail; 2017 Nov 13; 10(11):. PubMed ID: 29141857
    [Abstract] [Full Text] [Related]

  • 15. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
    Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP, ASTRONAUT Investigators and Coordinators.
    JAMA; 2013 Mar 20; 309(11):1125-35. PubMed ID: 23478743
    [Abstract] [Full Text] [Related]

  • 16. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
    Fudim M, White J, Pagidipati NJ, Lokhnygina Y, Wainstein J, Murin J, Iqbal N, Öhman P, Lopes RD, Reicher B, Holman RR, Hernandez AF, Mentz RJ.
    Circulation; 2019 Nov 12; 140(20):1613-1622. PubMed ID: 31542942
    [Abstract] [Full Text] [Related]

  • 17. Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction <50%.
    Ezekowitz JA, Lee DS, Tu JV, Newman AM, McAlister FA.
    Am J Cardiol; 2008 Jul 01; 102(1):79-83. PubMed ID: 18572040
    [Abstract] [Full Text] [Related]

  • 18. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.
    Mentz RJ, Allen BD, Kwasny MJ, Konstam MA, Udelson JE, Ambrosy AP, Fought AJ, Vaduganathan M, O'Connor CM, Zannad F, Maggioni AP, Swedberg K, Bonow RO, Gheorghiade M.
    Eur J Heart Fail; 2013 Jan 01; 15(1):61-8. PubMed ID: 22968743
    [Abstract] [Full Text] [Related]

  • 19. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.
    Florea VG, Rector TS, Anand IS, Cohn JN.
    Circ Heart Fail; 2016 Jul 01; 9(7):. PubMed ID: 27413037
    [Abstract] [Full Text] [Related]

  • 20. Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.
    Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Care; 2017 Dec 01; 40(12):1763-1770. PubMed ID: 28986504
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.